The invention provides a progesterone ethosome. Progesterone is encapsulated in an ethosome. The progesterone ethosome comprises the following components in percentage by weight: 0.1 to 1 percent of progesterone, 1 to 8 percent of lipid materials, 0 to 0.6 percent of
cholesterol, 20 to 50 percent of short-chain alcohols, 0 to 3 percent of
nonionic surfactant and the balance of water. The preparation method comprises the following steps of: mixing and dissolving the progesterone, the lipid materials, the
cholesterol and the short-chain alcohols to prepare an
alcohol phase; with stirring, adding the
alcohol phase into a
nonionic surfactant-containing aqueous phase to prepare primary
emulsion under the condition of stirring; homogenizing the primary
emulsion under a
high pressure to obtain asuspension; stirring the ethosome suspension for 15 to 30 minutes to perform emulsification for the second time; and curing the suspension by cooling the suspension at 0 to 4 DEG C to obtain the progesterone ethosome. Because the high-pressure homogenization method is adopted to prepare the progesterone ethosome, the progesterone ethosome is low in stimulation to
skin and high in transdermal delivery ability, and
metal ion pollution which is easy to cause by the probe
ultrasound method of the traditional homogenization method is avoided. Therefore, the progesterone ethosome is suitable for industrial production. The progesterone ethosome can be prepared into a transdermal
drug delivery system, a mucosal
drug delivery system, and topical dosage forms, such as a paster, a gel and the like. The progesterone ethosome is mainly applied to
hormone replacement therapy, secondary
amenorrhea, functional aplastic bleeding, premenstrual syndrome and the like clinically.